Rock Creek Pharmaceuticals Inc is a United States-based pharmaceutical development company. The Company is focused on the discovery, development and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its activities are focused on its lead compound, anatabine citrate (anatabine). Anatabine is a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics. The Company focuses on dermatological skin diseases, such as psoriasis, eczema and rare or orphan skin disorders, using its formulations of anatabine.

Employees

Sector

Pharmaceuticals

More about the company

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI

Market Cap	153K 135K 124K 116K 218K 14.47M 222K 1.49M 577K 7.14M 576K 563K 24.8M	P/E 2014	-0.87x	P/E 2015	-1.04x
Enterprise Value	20.01M 17.58M 16.19M 15.14M 28.4M 1.89B 28.92M 194M 75.26M 931M 75.15M 73.5M 3.23B	EV / Sales 2014	-	EV / Sales 2015	-
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

20-12-07	Rock Creek Pharmaceuticals, Inc. Went Out of Business	CI
20-02-05	Bankruptcy Judge Changed for Rock Creek Pharmaceuticals, Inc.	CI
18-12-20	Motion for Asset Sale Filed by Rock Creek Pharmaceuticals, Inc.	CI
18-01-10	Motion for Asset Sale Approved for Rock Creek Pharmaceuticals, Inc.	CI
16-09-27	Rock Creek Pharmaceuticals, Inc. Filed for Bankruptcy	CI
16-08-29	Rock Creek Pharmaceuticals, Inc. Receives Event of Default Redemption Notice from Hudson Bay Master Fund Ltd. and from Tenor Capital Management on Behalf of Alto Opportunity Master Fund	CI
16-08-10	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2016	CI
16-07-08	Rock Creek Pharmaceuticals, Inc. Announces Board Changes	CI
16-06-08	Rock Creek Pharmaceuticals, Inc. Reports Earnings results for the First Quarter Ended March 31, 2016	CI
16-03-29	Rock Creek Pharmaceuticals, Inc. announced that it has received $0.5 million in funding.	CI
16-03-22	Rock Creek Pharmaceuticals, Inc. Announces Earnings Results for the Year Ended December 31, 2015	CI
16-03-21	Rock Creek Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
15-11-19	Rock Creek Pharmaceuticals, Inc. Appoints Robert Scannell as Director	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+6.90%	+9.36%	+51.58%	+166.20%	1,006B
JOHNSON & JOHNSON	+3.51%	+9.61%	+66.78%	+54.93%	589B
ABBVIE INC.	+2.25%	+7.98%	+32.97%	+84.05%	430B
ROCHE HOLDING AG	-0.66%	+5.11%	+29.26%	+21.27%	331B
ASTRAZENECA PLC	+1.82%	+8.19%	+41.15%	+26.80%	288B
NOVARTIS AG	+0.22%	+6.75%	+31.51%	+42.02%	285B
NOVO NORDISK A/S	+0.73%	+8.53%	-26.22%	-40.85%	213B
AMGEN INC.	+1.93%	+4.43%	+28.98%	+60.19%	190B
GILEAD SCIENCES, INC.	+2.21%	+1.31%	+17.55%	+65.24%	154B
Average	+1.98%	+5.96%	+30.40%	+53.32%	387.31B
Weighted average by Cap.	+3.13%	+5.38%	+39.75%	+78.93%

	2014	2015
Net sales	-	-
Net income	-38.52M -33.83M -31.17M -29.15M -54.67M -3.63B -55.67M -374M -145M -1.79B -145M -141M -6.23B	-6.84M -6.01M -5.54M -5.18M -9.71M -646M -9.89M -66.47M -25.74M -318M -25.71M -25.14M -1.11B
Net Debt	-45K -39.53K -36.42K -34.05K -63.87K -4.25M -65.04K -437K -169K -2.09M -169K -165K -7.27M	19.86M 17.44M 16.07M 15.03M 28.18M 1.87B 28.7M 193M 74.68M 924M 74.57M 72.93M 3.21B

Star Scientific, Inc. Stock Nasdaq

Stocks

US85517P1012

Pharmaceuticals

Valuation: Star Scientific, Inc.

Latest news : Star Scientific, Inc.

Analysts' recommendations: Star Scientific, Inc.

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq Other stock markets
- ^USD	-